Key Points for Decision Makers {#FPar1}
==============================

A more comprehensive understanding of the economic models that exist for the management of heart failure is needed.This systematic literature review identified numerous publications that documented the various decision analytic modelling approaches, with a Markov cohort model the approach most commonly used to assess economic and societal implications in the heart failure setting.The majority of included studies employed New York Heart Association (NYHA) disease classifications to establish disease severity for modelling purposes.Further investigation is warranted to help underline the utility of reliable candidates of disease progression and their use in decision analytic models to provide a more precise estimate of the costs incurred while also guiding clinical decision making in the management of heart failure.

Introduction {#Sec1}
============

Heart failure (HF) has rapidly become a global health concern, with an estimated 26 million people living with this chronic health condition \[[@CR1]--[@CR4]\]. With the bulk of post-industrial nations experiencing a demographic shift, owing mostly to a dramatic growth in the aging population \[[@CR5]\], it is not surprising this epidemiologic transition is expected to lead to an increase in the global prevalence and incidence of HF in coming years \[[@CR2], [@CR6]\]. Numerous phenotypes for HF exist and are often defined by left-ventricular ejection fraction function \[[@CR7]\]. These typically encompass HF with reduced ejection fraction (HFrEF), which reflects systolic dysfunction indicative of impaired contraction in the left ventricle, and HF with preserved ejection fraction (HFpEF), characterized by abnormal relaxation of the left ventricle \[[@CR8]\].

Few treatments specific to patients with HFpEF are available (e.g. diuretics, revascularization for ischaemia, blood pressure control), though evidence indicating improvements in survival based on these pharmacologic therapies within this patient subset is somewhat lacking. A number of pharmacologic treatments are also available for those with HFrEF, including (but not limited to) angiotensin-converting enzyme inhibitors, beta-blockers, angiotensin-II receptor antagonists, mineralocorticoid receptor antagonists and angiotensin receptor inhibitors. Two additional treatments that have recently gained approval for use in the management of HFrEF include sacubitril/valsartan, a first-in-class angiotensin receptor neprilysin inhibitor, and ivabradine, a hyperpolarization-activated cyclic nucleotide-gated channel blocker. In light of these newly approved treatments and those that currently exist in the HF setting, understanding of the economic implications relative to the cost-effectiveness profiles of these pharmacologic regimens needs to improve.

In 2011, Goehler et al. \[[@CR9]\] performed a systematic literature review (SLR) of the extant economic modelling approaches available for HF in an effort to examine their usefulness for evaluating health technologies in HF. Several detailed decision models were identified for assessing the various HF technologies, though the bulk of these models differed considerably according to their modelling complexity, approach and underlying assumptions \[[@CR9]\]. The majority of these models further relied on New York Heart Association (NYHA) functional classifications as a proxy of disease extent and severity \[[@CR9]\].

We conducted an SLR to evaluate published economic models on pharmacologic treatments that reported on health economic outcomes among adults with HF. In particular, we sought to provide an update of the available literature following the article by Goehler et al. \[[@CR9]\], which examined data up to June 2010. We further wanted to examine in detail the core modelling specifications and structures as well as key features that were documented in more recently published economic models in the HF patient population.

Methods {#Sec2}
=======

Literature Review {#Sec3}
-----------------

We performed an SLR and identified relevant citations by searching a number of literature databases, including MEDLINE, Embase, the National Health Service Economic Evaluation Database, the Cost-Effectiveness Analysis Registry, the ScHARR Health Utilities Database and Cochrane Library Database using key search terms (Electronic Supplementary Material \[ESM\] 1). To identify the most up-to-date studies pertinent to current clinical practice, the present SLR aimed to include only data published since 1997 (i.e. up until November 2017). The search strategies were confined to all cost-effectiveness studies conducted in human patients with HF. Principal and practical guidelines advocated by the Cochrane Collaboration Handbook \[[@CR10]\] and the Centre for Reviews and Dissemination \[[@CR11]\] were also employed (where relevant) in an effort to limit any risk of bias and error.

Study Eligibility {#Sec4}
-----------------

This SLR utilized the PICOS (Population, Intervention, Comparator, Outcomes, and Study) design criteria for defining relevant inclusion and exclusion terms. In brief, studies were retained for further analysis if they included adult patients who had HF and were aged ≥ 18 years, provided details related to a pharmacologic treatment for HF and documented any mathematical model of cost-effectiveness specific to patients with HF who received a pharmacologic treatment. We subsequently excluded studies that were observational, experimental, preclinical, pharmacokinetic or pharmacodynamic in nature; a case report or case series (ten or fewer patients); a letter to the editor, opinion piece or review article; or published before 1997.

Study Selection {#Sec5}
---------------

The titles and abstracts of all retrieved search records were screened to identify any relevant references for inclusion (as per the National Institute for Health and Care Excellence methods guide \[[@CR12]\]). Full publications for all retained records were subsequently examined in detail, with a final list of relevant studies compiled thereafter. Both the search and the screening phases were independently conducted by two trained investigators (AB and FON). Any disagreements were resolved through further discussion or by consensus with a senior investigator (GDT). Figure [1](#Fig1){ref-type="fig"} presents a PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) flow diagram displaying the number of retained studies and a list of excluded studies. In an effort to evaluate the quality of models retrieved from the study selection process, we reviewed good modelling practice methods and employed the CHEERS (Consolidated Health Economic Evaluation Reporting Standards) statement checklist \[[@CR13], [@CR14]\].Fig. 1Flow chart displaying the number of publications included as well as the number of publications that were excluded, with reasons

Data Summary {#Sec6}
------------

Data abstracted from the retained publications included study design and population characteristics, model structure and specifications, and specific model outcomes, which are summarized according to the specific research questions, "What is the current availability of cost-effectiveness models for pharmacologic treatments in HF?"; "What are the core model specifications (e.g. types and structures, etc.) of previously published health economic models in HF?"; and "What are the key drivers derived from previously conducted cost-effectiveness analyses in HF?" Data are summarized using text where relevant, or displayed in accompanying tables and figures, as necessary. A brief summary describing the quality of studies based on the CHEERS statement checklist \[[@CR13]\] for each research question is also reported. This method aimed to address the appropriateness of the modelling approaches and structures, the quality of reporting, and possible limitations that might have impaired the validity and generalizability of the study findings.

Results {#Sec7}
=======

Literature Search {#Sec8}
-----------------

The original SLR search yielded a total of 3671 citations. Of these, 65 were duplicates that were subsequently removed. A further 3510 articles failed to meet the inclusion criteria based on their titles and abstracts at screening, and an additional 32 publications were excluded for specific reasons as outlined in Fig. [1](#Fig1){ref-type="fig"}.

Description of Studies {#Sec9}
----------------------

Overall, 64 articles were suitable for inclusion. The ages of the patient populations ranged from 20 to 93 years. The proportion of men within each patient cohort also varied, with a minimum and maximum of 22 and 89% documented across publications. Altogether, the geographic regions of the populations in the 64 publications encompassed 15 different countries: the most commonly identified nations included the USA (*n* = 16 \[25%\]) \[[@CR15]--[@CR30]\], the UK (*n* = 16 \[25%\]) \[[@CR31]--[@CR46]\] and Canada (*n* = 5 \[8%\]) \[[@CR24], [@CR47]--[@CR50]\]. A total of 48 (75%) publications included in this review reported their source of funding \[[@CR15], [@CR16], [@CR18], [@CR22], [@CR24]--[@CR35], [@CR37]--[@CR42], [@CR44], [@CR45], [@CR47], [@CR48], [@CR50]--[@CR71]\]. Of the included publications, the most commonly reported pharmacologic treatments administered to patients with HF included eplerenone (*n* = 12 \[19%\]), ramipril (*n* = 11 \[17%\]) enalapril (*n* = 8 \[13%\]) and ivabradine (*n* = 6 \[9%\]).

Overview of Economic Model Structure and Specifications {#Sec10}
-------------------------------------------------------

### Markov Model Approach {#Sec11}

Most of the publications provided reasonable details in relation to the types of modelling approaches employed (Table [1](#Tab1){ref-type="table"}). The most common modelling approaches used included a Markov cohort model type (*n* = 28 \[41%\]) \[[@CR15], [@CR17], [@CR19], [@CR22], [@CR23], [@CR26], [@CR27], [@CR32]--[@CR34], [@CR38]--[@CR40], [@CR44], [@CR48], [@CR49], [@CR51], [@CR52], [@CR58], [@CR66]--[@CR69], [@CR72]--[@CR76]\]. Given the versatility of the Markov model approach in adopting different types of health states patients can potentially experience, this method was further categorized into health state classifications. These typically included an "alive or dead" state \[[@CR17], [@CR19], [@CR32], [@CR33], [@CR39], [@CR51], [@CR67]\], NYHA disease classification \[[@CR15], [@CR23], [@CR52], [@CR58], [@CR68]\], cardiovascular events \[[@CR22], [@CR26], [@CR27], [@CR38], [@CR44], [@CR48], [@CR66], [@CR72], [@CR74]--[@CR76]\] and hospitalization states \[[@CR27], [@CR49], [@CR66], [@CR72], [@CR74]--[@CR76]\]. Specific Markov model structure was unclear in four studies \[[@CR34], [@CR40], [@CR69], [@CR73]\]. Seven studies focused on a two-state Markov approach based around the "alive" and "dead" states \[[@CR17], [@CR19], [@CR32], [@CR33], [@CR39], [@CR51], [@CR67]\]. Five studies that employed a Markov cohort model approach used the NYHA disease classification system \[[@CR15], [@CR23], [@CR52], [@CR58], [@CR68]\]. Three of these studies \[[@CR23], [@CR52], [@CR58]\] incorporated five health states: one for each NYHA class and a separate one for death. Another publication \[[@CR68]\] used four health states according to each of the NYHA classifications to determine health states. A number of methods were employed for modelling according to the NYHA disease classification system, which were based on classifying patients according to their level of HF severity. Some studies employed a constant movement of patients (i.e. belonging to the same health state within the study timeframe) \[[@CR23], [@CR52]\], whereas others provided a greater level of detail surrounding transition probabilities \[[@CR68]\]. NYHA classifications were generally derived from trial data or from secondary sources when data were unavailable, which may have influenced the estimation of patient ratios within respective NYHA clusters.Table 1Overview of economic models reported in publicationsStudy, countryDisease classification systemHF typeModel specificationsModelling outcomes assessedType of scenario/sensitivity analysisKey model driversErhardt et al. \[[@CR63]\] SwedenNYHAUnclear*Core model/adaptation:* Adaptation\
*Study type:* Cost effectiveness\
*Model type:* 'Real-world' partition survival analysis\
*Perspective:* Third-party payer\
*Time horizon:* 3.8 years\
*Discount rate:* 5% for both costs and health outcomesLYG, costs, ICERs, WTPOWSA; the key model drivers were varied to establish their effect on the outcomeHospital costs\
Number of rehospitalizations for HFSchadlich et al. \[[@CR70]\] GermanyNYHAUnclear*Core model/adaptation:* Core model\
*Study type:* Cost effectiveness\
*Model type:* Partition survival model\
*Perspective:* Payer\
*Time horizon:* 3.8 years\
*Discount rate:* 5% for costsLYG, costs, ICERsDSA\
Weibull estimation of survival probability and LYGTreatment duration\
Number of rehospitalizations per patient\
Inpatient treatment for decompensated HFAnderson et al. \[[@CR53]\] South AfricaNYHAUnclear*Core model/adaptation:* Adaptation\
*Study type:* Cost utility\
*Model type:* Partition survival model\
*Perspective:* Third-party payer\
*Time horizon:* 3.8 years\
*Discount rate:* 0%, 5% and 10% for costs. 5% for health outcomesLYG, costs, ICERsAnalysis established best- and worst-case scenariosTreatment durationHart et al. \[[@CR65]\] SpainNYHAUnclear*Core model/adaptation:* Adaptation\
*Study type:* Cost effectiveness\
*Model type:* Area under the survival curve analysis of survival and rehospitalization probability\
*Perspective:* Payer\
*Time horizon:* 3.8 years\
*Discount rate:* 6% for both costs and health outcomesLYG, costs, ICERsEstablishes the effect of additional costs and non-hospital costs on the ICER for the interventionTreatment duration\
Length of hospital stayAdemi et al. \[[@CR51]\] AustraliaNYHAChronic*Core model/adaptation:* Core model\
*Study type:* Cost utility\
*Model type:* Markov model with four transition states with 1-year cycle lengths\
*Perspective:* Payer\
*Time horizon:* 10 years\
*Discount rate:* 5% for both costs and health outcomesQALYs, LYG, costs, ICERs, WTPUnivariate analysisEfficacy measures (predominantly those regarding CV mortality)\
Drug costAdemi et al. \[[@CR52]\] AustraliaNYHAChronic*Core model/adaptation:* Core model\
*Study type:* Cost utility\
*Model type:* Five-health-state Markov model with 1-year cycle lengths\
*Perspective:* Payer\
*Time horizon:* 10 years\
*Discount rate:* 5% for both costs and health outcomesQALYs, LYG, costs, ICERs, WTPScenario analysisNumber of hospitalizationsLee et al. \[[@CR41]\] UK and SpainNYHAChronic*Core model/adaptation:* Core model\
*Study type:* Cost utility\
*Model type:* Discrete-event simulation model determining risk of hospitalization for HF, new-onset of AF, AEs, treatment discontinuation, and mortality\
*Perspective:* Payers\
*Time horizon:* Lifetime\
*Discount rate:* 3.5% for health outcomes for the UK model and 3% for the Spanish modelQALYs, LYG, costs, ICERs, WTPDSA and PSADrug cost\
Cost of disease management and monitoring\
Number of hospitalizationsThanh et al. \[[@CR50]\] CanadaUnclearUnclear*Core model/adaptation:* Adaptation\
*Study type:* Cost utility\
*Model type:* Discrete-event simulation model of hospitalizations, AEs, AF, device implantation, discontinuation, and death\
*Perspective:* Healthcare\
*Time horizon:* Lifetime\
*Discount rate:* 3% for both costs and health outcomesQALYs, LYG, costs, ICERs, WTPScenario analysis and OWSADrug cost\
Scale parameters of Weibull distributions estimating time to event of device implantation\
CV hospitalization for patients receiving interventionCADTH \[[@CR47]\] CanadaNYHAChronic*Core model/adaptation:* Core model\
*Study type:* Cost utility\
*Model type:* Discrete-event simulation model of hospitalization, AEs, discontinuation, and AF, resulting in either mortality or device implantation\
*Perspective:* Ministry of Health (governmental)\
*Time horizon:* Lifetime\
*Discount rate:* 5% for both costs and health outcomesQALYs, LYG, costs, ICERsDSA and PSANot reportedSMC \[[@CR35]\] ScotlandUnclearUnclear*Core model/adaptation:* Core model\
*Study type:* Cost utility\
*Model type:* Discrete-event simulation model\
*Perspective:* NHS\
*Time horizon:* Lifetime\
*Discount rate:* Not reportedQALYs, costs, ICERsScenario analysisMortalityAWMSG \[[@CR31]\] WalesUnclearUnclear*Core model/adaptation:* Core model\
*Study type:* Cost utility\
*Model type:* Discrete-event simulation model\
*Perspective:* NHS\
*Time horizon:* Lifetime\
*Discount rate:* 3.5% on both costs and health outcomesQALYs, LYG, costs, ICERs, WTPOWSADistribution parameters for CV mortality\
Number of HF hospitalizations\
Utility decrements associated with ageWeintraub et al. \[[@CR29]\] USAUnclearUnclear*Core model/adaptation:* Core model\
*Study type:* Cost utility\
*Model type:* Trial- and registry-based analysis\
*Perspective:* Societal\
*Time horizon:* 16 months\
*Discount rate:* 3% for both costs and health outcomesQALYs, LYG, costs, ICERs, WTPBootstrap analysisAge\
Use of blocker treatment after AMI\
Use of life-saving interventionsde Pouvourville et al. \[[@CR61]\] FranceUnclearUnclear*Core model/adaptation:* Adaptation\
*Study type:* Cost utility\
*Model type:* Trial- and registry-based analysis\
*Perspective:* Partially societal\
*Time horizon:* 16 months\
*Discount rate:* 5% for both costs and health outcomesQALYs, LYG, costs, ICERsPSALong-term survivalZhang et al. \[[@CR30]\] USAUnclearUnclear*Core model/adaptation:* Adaptation\
*Study type:* Cost utility\
*Model type:* Trial-based analysis\
*Perspective:* Societal\
*Time horizon:* 16 months\
*Discount rate:* 3% for both costs and health outcomesQALYs, LYG, costs, ICERs, WTPNot reportedPost-trial costsMcKenna et al. \[[@CR44]\] UKUnclearUnclear*Core model/adaptation:* Core model\
*Study type:* Cost utility\
*Model type:* Markov model with 1-year cycle lengths\
*Perspective:* NHS\
*Time horizon:* Lifetime\
*Discount rate:* 3.5% for both costs and health outcomesQALYs, costs, ICERs, WTPSensitivity analysis was not specified but established key model driversTreatment efficacyOllendorf et al. \[[@CR25]\] USANYHAChronic*Core model/adaptation:* Core model\
*Study type:* Cost effectiveness\
*Model type:* Trial-based analysis\
*Perspective:* Payers\
*Time horizon:* Lifetime\
*Discount rate:* Not reportedQALYs, costs, ICERs, WTP, VBPSensitivity analysis was not specified but established key model driversAssumed duration of improved outcomes with the intervention (sacubitril/valsartan)King et al. \[[@CR23]\] USANYHAChronic*Core model/adaptation:* Core model\
*Study type:* Cost utility\
*Model type:* Markov model using NYHA disease classification and death to establish health states with 3-month cycle lengths\
*Perspective:* Third-party payer\
*Time horizon:* Lifetime\
*Discount rate:* 3% for both costs and health outcomesQALYs, LYG, costs, ICERs, WTPDSA and PSAProbability of CV deathSandhu et al. \[[@CR27]\] USANYHAChronic*Core model/adaptation:* Core model\
*Study type:* Cost utility\
*Model type:* Markov model of hospitalization reasons, ED visit for HF and death, with 1-month cycle lengths\
*Perspective:* Societal\
*Time horizon:* Lifetime\
*Discount rate:* 3% for both costs and health outcomesQALYs, LYG, costs, ICERs, WTPSensitivity analysis was not specified but established key model driversSurvivalRamos et al. \[[@CR69]\] NetherlandsNYHAChronic*Core model/adaptation:* Adaptation\
*Study type:* Cost utility\
*Model type:* Markov model with a half-cycle correction and 1-month cycle lengths\
*Perspective:* Societal\
*Time horizon:* Lifetime\
*Discount rate:* 4% for costs and 1.5% for health outcomesQALYs, LYG, costs, ICERs, WTPScenario analysisHospitalization\
Mortalityvan der Pol et al. \[[@CR75]\] NetherlandsNYHAChronic*Core model/adaptation:* Core model\
*Study type:* Cost utility\
*Model type:* Markov model with four health states and 1-month cycle lengths\
*Perspective:* Healthcare payer\
*Time horizon:* Lifetime\
*Discount rate:* 4% for costs and 1.5% for health outcomesQALYs, LYG, costs, ICERs, WTP, VBPUnivariate analysisRisk of death\
Utility of patients who are not hospitalized\
QALYsNICE \[[@CR32]\] EnglandNYHAChronic*Core model/adaptation:* Core model\
*Study type:* Cost utility\
*Model type:* Markov model with a half-cycle correction and 1-month cycle lengths\
*Perspective:* NHS\
*Time horizon:* Lifetime\
*Discount rate:* 3.5% for both costs and health outcomesQALYs, LYG, costs, ICERs, WTPSensitivity analysis was not specified but established key model driversTreatment effect\
The constant term in the statistical model of all-cause mortalitySMC \[[@CR33]\] ScotlandNYHAChronic*Core model/adaptation:* Core model\
*Study type:* Cost utility\
*Model type:* Two-state, alive and dead, Markov model\
*Perspective:* NHS\
*Time horizon:* Lifetime\
*Discount rate:* Not reportedQALYs, costs, ICERsA range of sensitivity analyses and scenario analysisSurvival estimates\
Duration of treatment effect\
Time horizonICER \[[@CR15]\] USANYHAChronic*Core model/adaptation:* Core model\
*Study type:* Cost utility\
*Model type:* Markov model with 1-month cycle lengths\
*Perspective:* Third-party payer\
*Time horizon:* Lifetime\
*Discount rate:* 3% for both costs and health outcomesQALYs, LYG, costs, ICERs, WTP, VBPSensitivity analysis was not specified but established key model driversDuration of treatment effect\
Price of drugVarney \[[@CR46]\] UKNYHAChronic*Core model/adaptation:* Core model\
*Study type:* Cost effectiveness\
*Model type:* Trial-based analysis\
*Perspective:* NHS\
*Time horizon:* 5 years\
*Discount rate:* 6% for both costs and health outcomesLYG, costs, ICERsSensitivity analysis was not specified but established key model driversAnnual rate of hospitalizationEkman et al. \[[@CR62]\] SwedenNYHAChronic*Core model/adaptation:* Core model\
*Study type:* Cost effectiveness\
*Model type:* Trial-based analysis\
*Perspective:* Societal\
*Time horizon:* 2.3 years\
*Discount rate:* 3% for both costs and health outcomes. Costs occurring within the context of the clinical trial have not been discountedLYG, costs, ICERs, WTPOWSACost of life-years gainedPolistena et al. \[[@CR73]\] ItalyNYHAChronic*Core model/adaptation:* Adaptation\
*Study type:* Cost effectiveness\
*Model type:* Markov model\
*Perspective:* NHS\
*Time horizon and discount rate:* Not reportedQALYs, LYG, costs, ICERs, WTPPSANot reportedKansal et al. \[[@CR22]\] USANYHAChronic*Core model/adaptation:* Core model\
*Study type:* Cost utility\
*Model type:* Markov model with 1-month cycle lengths\
*Perspective:* Payer\
*Time horizon:* 10 years\
*Discount rate:* Not reportedQALYs, LYG, costs, ICERs, WTPPSATime horizon\
Treatment effect on HF hospitalization and mortalityEdwards et al. \[[@CR39]\] EnglandNYHAChronic*Core model/adaptation:* Core model\
*Study type:* Cost utility\
*Model type:* Alive and dead Markov model, with half-cycle correction and 1-month cycle lengths\
*Perspective:* NHS\
*Time horizon:* Lifetime\
*Discount rate:* 3.5% for both costs and health outcomesQALYs, LYG, costs, ICERs, WTPDSA and PSATreatment effectSMC \[[@CR34]\] ScotlandNYHAChronic*Core model/adaptation:* Core model\
*Study type:* Cost utility\
*Model type:* Markov model\
*Perspective:* NHS\
*Time horizon:* Lifetime\
*Discount rate:* Not reportedQALYs, costs, ICERsNot reportedNot reportedBackhouse et al. \[[@CR36]\] UKUnclearChronic*Core model/adaptation:* Core model\
*Study type:* Cost effectiveness\
*Model type:* Trial-based analysis\
*Perspective:* NHS\
*Time horizon:* 5 years\
*Discount rate:* 6% for both costs and health outcomesLYG, costs, ICERsSensitivity analysis was not specified but established key model driversLong-term survivalMalik et al. \[[@CR43]\] UKUnclearChronic*Core model/adaptation:* Core model\
*Study type:* Cost effectiveness and cost consequence\
*Model type:* Trial-based analysis\
*Perspective:* NHS\
*Time horizon:* Lifetime\
*Discount rate:* 6% for both costs and health outcomesICERs, WTPOWSACost of drugLamy et al. \[[@CR24]\] USA and CanadaUnclearChronic*Core model/adaptation:* Core model\
*Study type:* Cost effectiveness\
*Model type:* Trial-based analysis\
*Perspective:* Third-party payer\
*Time horizon:* 4.5 years\
*Discount rate:* 3% for costsCosts, ICERs, WTPNot reportedNot reportedBjorholt et al. \[[@CR54]\] SwedenUnclearChronic*Core model/adaptation:* Core model\
*Study type:* Cost effectiveness\
*Model type:* Trial-based analysis\
*Perspective:* Societal\
*Time horizon:* 4.5 years\
*Discount rate:* 3% for both costs and health outcomesLYG, costs, ICERs, WTPNot specifiedNot reportedBeard et al. \[[@CR37]\] UKUnclearChronic*Core model/adaptation:* Core model\
*Study type:* Cost effectiveness\
*Model type:* Trial-based analysis\
*Perspective:* NHS\
*Time horizon:* 5 years\
*Discount rate:* 6% for both costs and health outcomesLYG, costs, ICERs, WTPNot specifiedNot reportedGrover et al. \[[@CR48]\] CanadaNYHAChronic*Core model/adaptation:* Core model\
*Study type:* Cost utility\
*Model type:* Markov model with 1-year cycle lengths\
*Perspective:* NHS\
*Time horizon:* Lifetime\
*Discount rate:* 3% for both costs and health outcomesQALYs, LYG, ICERsNot reportedLong-term survivalColombo et al. \[[@CR57]\] ItalyNYHAChronic*Core model/adaptation:* Core model\
*Study type:* Cost effectiveness\
*Model type:* Trials-based analysis\
*Perspective:* NHS\
*Time horizon:* 2 years\
*Discount rate:* 3% for both costs and health outcomesLYG, costs, ICERsSensitivity analysis was not specified but established key model driversHospital admissionsAngus et al. \[[@CR16]\] USANYHAChronic*Core model/adaptation:* Core model\
*Study type:* Cost effectiveness\
*Model type:* Trial-based analysis\
*Perspective:* Societal\
*Time horizon:* 18 months\
*Discount rate:* 3% for both costs and health outcomesLYG, costs, ICERs, WTPSensitivity analysis was not specified but established key model driversCost of drug\
Cost of hospital stayBorghi et al. \[[@CR55]\] multi-countryKillipMixed*Core model/adaptation:* Core model\
*Study type:* Cost effectiveness\
*Model type:* Trial-based analysis\
*Perspective:* Third-party payer\
*Time horizon:* 12 months\
*Discount rate:* Not reportedCosts, ICERs, WTPNot specifiedNot reportedPradelli et al. \[[@CR68]\] ItalyNYHAChronic*Core model/adaptation:* Core model\
*Study type:* Cost utility\
*Model type:*Markov model using NYHA disease classification and death to establish health states with 1-month cycle lengths\
*Perspective:* NHS\
*Time horizon:* 10 years\
*Discount rate:* 3.5% for both costs and health outcomesQALYs, LYG, costs, ICERs, WTPSensitivity analysis was not specified but established key model driversHospitalizationLorgelly et al. \[[@CR42]\] UKNYHAChronic*Core model/adaptation:* Core model\
*Study type:* Cost effectiveness\
*Model type:* Trial-based analysis\
*Perspective:* NHS\
*Time horizon:* 3 years\
*Discount rate:* 3.5% for both costs and health outcomesLYG, costs, ICERs, WTPSensitivity analysis was not specified but established key model driversCost of statin treatment, hospitalizations and procedures for major CV eventsde Lissovoy et al. \[[@CR18]\] USANYHAAcute*Core model/adaptation:* Core model\
*Study type:* Cost effectiveness\
*Model type:* Trial-based analysis\
*Perspective:* Hospital\
*Time horizon:* Lifetime\
*Discount rate:* Not reportedLYG, costs, ICERsSensitivity analysis was not specified but established key model driversCost of treatment\
Long-term survivalde Lissovoy et al. \[[@CR60]\] multi-countryUnclearAcute*Core model/adaptation:* Core model\
*Study type:* Cost effectiveness\
*Model type:* Trials-based analysis\
*Perspective:* Third-party payer\
*Time horizon:* Lifetime\
*Discount rate:* Not reportedCosts, ICERs, WTPBootstrap analysisLong-term survivalCleland et al. \[[@CR56]\] multi-countryUnclearMixed*Core model/adaptation:* Core model\
*Study type:* Cost effectiveness\
*Model type:* Trials-based analysis\
*Perspective:* Third-party payer\
*Time horizon:* 4 years\
*Discount rate:* 3% for both costs and health outcomesLYG, ICERs, WTPSensitivity analysis was not specified but established key model driversLong-term survival\
HospitalizationSculpher et al. \[[@CR45]\] UKNYHAChronic*Core model/adaptation:* Core model\
*Study type:* Cost effectiveness\
*Model type:* Trial-based analysis\
*Perspective:* NHS\
*Time horizon:* 4 years\
*Discount rate:* 6% for costs and 2% for health outcomesLYG, costs, ICERs, WTPSensitivity analysis was not specified but established key model driversRisk of death\
HospitalizationDelea et al. \[[@CR19]\] USANYHAChronic*Core model/adaptation:* Core model\
*Study type:* Cost effectiveness\
*Model type:* Six-state Markov model with 1-month cycle lengths\
*Perspective:* Not reported\
*Time horizon:* Lifetime\
*Discount rate:* 3% for both costs and health outcomesLYG, costs, ICERsNot specifiedNot reportedRosen et al. \[[@CR26]\] USAUnclearChronic*Core model/adaptation:* Core model\
*Study type:* Cost utility\
*Model type:* Markov model with 1-year cycle lengths\
*Perspective:* Payer\
*Time horizon:* Lifetime\
*Discount rate:* 3% for both costs and health outcomesLYG, costs, ICERs, WTPOWSAHazard ratios for RCA, CHF, and MIInomata et al. \[[@CR66]\] JapanNYHAChronic*Core model/adaptation:* Core model\
*Study type:* Cost effectiveness\
*Model type:* Four-state Markov model with 1-month cycle length\
*Perspective:* Payer\
*Time horizon:* Lifetime\
*Discount rate:* 3% for both costs and health outcomesLYG, costsNot specifiedNot reportedGregory et al. \[[@CR21]\] USAUnclearUnclear*Core model/adaptation:* Core model\
*Study type:* Cost effectiveness\
*Model type:* Trial- and registry-based data analyses\
*Perspective:* Not reported\
*Time horizon:* Lifetime\
*Discount rate:* 5% for both costs and health outcomesLYG, costs, ICERsSensitivity analysis was not specified but established key model driversPrice of drug\
Relative mortality riskBarry \[[@CR72]\] IrelandUnclearChronic*Core model/adaptation:* Core model\
*Study type:* Cost effectiveness\
*Model type:* Markov model\
*Perspective:* Healthcare\
*Time horizon:* 10 years\
*Discount rate:* 5% for costs and 1.5% for health outcomesICERsOWSAPrice of drugCowper et al. \[[@CR58]\] multi-countryUnclearChronic*Core model/adaptation:* Core model\
*Study type:* Cost effectiveness\
*Model type:* Markov model using NYHA disease classification and death to establish health states with 6-month cycle lengths\
*Perspective:* Societal, Medicare, hospital, physician, and patient\
*Time horizon:* 5 years\
*Discount rate:* 3% for both costs and health outcomesCostsOWSAClinical efficacy of beta-blockersGlick et al. \[[@CR64]\] multi-countryNYHAMixed*Core model/adaptation:* Core model\
*Study type:* Cost utility\
*Model type:* Decision analytic model\
*Perspective:* Payers\
*Time horizon:* Not reported\
*Discount rate:* 3% for both costs and health outcomesQALYs, costsOWSAHF classificationCaro et al. \[[@CR77]\] multi-countryNYHAChronic*Core model/adaptation:* Core model\
*Study type:* Cost effectiveness\
*Model type:* Discrete-event simulation\
*Perspective:* Payer\
*Time horizon:* 2 years\
*Discount rate:* 3% for both health costs and outcomesCostsNot specifiedNot reportedGerhard et al. \[[@CR20]\] USANYHAUnclear*Core model/adaptation:* Core model\
*Study type:* Cost effectiveness\
*Model type:* Decision-tree model\
*Perspective:* Not reported\
*Time horizon:* 6 months\
*Discount rate:* Not reportedLYG, costs, ICERsNot reportedNot reportedDasbach et al. \[[@CR59]\] multi-countryNYHAUnclear*Core model/adaptation:* Core model\
*Study type:* Cost effectiveness\
*Model type:* Trial-based analysis\
*Perspective:* Third-party payer\
*Time horizon:* Not reported\
*Discount rate:* 3% for both costs and health outcomesCosts, WTPSensitivity analysis was not specified but established key model driversOverall survival\
Resource dataLevy et al. \[[@CR49]\] CanadaUnclearUnclear*Core model/adaptation:* Adaptation\
*Study type:* Cost effectiveness\
*Model type:* 5-state Markov model with 1-month cycle lengths\
*Perspective:* Payer\
*Time horizon:* 20 years\
*Discount rate:* 3% for both costs and health outcomesLYG, costs, ICERsPSADiscount rate\
Choice of out-of-hospital mortality rateMcMurray et al. \[[@CR78]\] NAUnclearUnclear*Core model/adaptation:* Not reported\
*Study type:* Cost effectiveness\
*Model type:* Survival analysis\
*Perspective and time horizon:* Not reported\
*Discount rate:* 6% for both costs and health outcomesLYG, costs, ICERsNot specifiedNot reportedVan Genugten et al. \[[@CR71]\] NetherlandsUnclearUnclear*Core model/adaptation:* Core model\
*Study type:* Cost effectiveness\
*Model type:* Survival analysis\
*Perspective:* Not reported\
*Time horizon:* Lifetime\
*Discount rate:* 4% for both costs and health outcomesQALYs, LYG, costs, ICERs, WTPOWSA and PSANot reportedCowie et al. \[[@CR38]\] UKNYHAChronic*Core model/adaptation:* Core model\
*Study type:* Cost utility\
*Model type:* Markov model with 1-year cycle lengths\
*Perspective:* Payer\
*Time horizon:* Lifetime\
*Discount rate:* 4% for both costs and health outcomesQALYs, LYG, costs, ICERs, WTPNot specifiedNot reportedTilson et al. \[[@CR74]\] IrelandUnclearUnclear*Core model/adaptation:* Adaptation\
*Study type:* Cost effectiveness\
*Model type:* Markov model\
*Perspective:* Payer\
*Time horizon:* 10 years\
*Discount rate:* 5% for both costs and health outcomesICERsNot specifiedNot reportedKourlaba et al. \[[@CR67]\] GreeceNYHAChronic*Core model/adaptation:* Adaptation\
*Study type:* Cost effectiveness\
*Model type:* Two-state, alive and dead, Markov model\
*Perspective:* Third-party payer\
*Time horizon:* Lifetime\
*Discount rate:* 3.5% for both costs and health outcomesQALYs, LYG, costs, ICERs, WTPScenario analysisNot reportedBanka et al. \[[@CR17]\] USANYHAUnclear*Core model/adaptation:* Not reported\
*Study type:* Cost effectiveness\
*Model type:* Two-state, alive and dead, Markov model\
*Perspective:* Single payer and healthcare\
*Time horizon:* Lifetime\
*Discount rate:* 3.5% for both costs and health outcomesQALYs, LYG, costs, ICERsSensitivity analysis was not specified but established key model driversProbability of death\
Hospitalization\
Total costs\
Length of HF treatment's risk reduction on mortality and hospitalizationYao et al. \[[@CR76]\] multi-countryNYHAChronic*Core model/adaptation:* Core model\
*Study type:* Cost effectiveness\
*Model type:* Markov model with 1-month cycle lengths\
*Perspective:* Payer, NHS\
*Time horizon:* Lifetime\
*Discount rate:* 4% for both costs and health outcomesQALYs, LYG, costs, ICERs, VBPScenario analysisNot reportedGriffiths et al. \[[@CR40]\] UKNYHAChronic*Core model/adaptation:* Core model\
*Study type:* Cost effectiveness\
*Model type:* Two-state Markov model, with 1-month cycle lengths\
*Perspective:* NHS\
*Time horizon:* Lifetime\
*Discount rate:* 4% for both costs and health outcomesQALYs, LYG, costs, ICERs, WTPDSA and PSATreatment effectVera-Llonch et al. \[[@CR28]\] USANYHAChronic*Core model/adaptation:* Core model\
*Study type:* Cost minimization\
*Model type:* Trial-based analysis\
*Perspective, time horizon, discount rate:* NACostsNot specifiedNot reported*AE* adverse event, *AF* atrial fibrillation, *AMI* acute myocardial infarction, *CHF* chronic heart failure, *CV* cardiovascular, *DSA* deterministic sensitivity analysis, *ED* emergency department, *HF* heart failure, *ICER* incremental cost-effectiveness ratio, *LYG* life-years gained, *MI* myocardial infarction, *NA* not applicable, *NHS* National Health Service, *NYHA* New York Heart Association, *OWSA* one-way sensitivity analysis, *PSA* probabilistic sensitivity analysis, *QALYs* quality-adjusted life-years, *RCA* root cause analysis, *VBP* value-based pricing, *WTP* willingness to pay

Within nine articles that used the Markov model method, HF was often modelled alongside other cardiovascular health states \[[@CR15], [@CR27], [@CR32], [@CR34], [@CR38], [@CR66], [@CR72], [@CR74], [@CR76]\]. Aside from HF, other cardiovascular conditions concurrently modelled included myocardial infarction and post cardiovascular events \[[@CR34], [@CR76]\]. Few publications employed hospitalization states with hazard ratios \[[@CR75]\] or rate ratios \[[@CR27]\] that were applied to transition probabilities in an effort to account for between-treatment effects. One publication \[[@CR27]\] adjusted for mortality to increase with age and calibrated mortality rates over the course of the trial to reflect changing probabilities as patients progressed through the model with increasing age. Shorter timeframes of approximately 10 years were implemented in some publications \[[@CR74]\], whereas others adopted a lifetime horizon \[[@CR27], [@CR38], [@CR66], [@CR75], [@CR76]\]. One study used a random effects meta-analysis to examine the importance of hospitalization as a health state, which was dependent on the number of hospitalizations and death \[[@CR49]\]. Other studies associated hospitalization with mortality by implementing survival methods or lifetime tables, linked either directly or independently to hospitalization as a central state of health \[[@CR75]\].

### Trial-Based Analytic Approach and Event Simulation {#Sec12}

A number of the retrieved articles followed a trial-based analytic approach (*n* = 22 \[34%\]) \[[@CR16], [@CR18], [@CR21], [@CR24], [@CR25], [@CR28]--[@CR30], [@CR36], [@CR37], [@CR42], [@CR43], [@CR45], [@CR46], [@CR54]--[@CR57], [@CR59]--[@CR62]\]. Some studies \[[@CR30]\] analysed clinical trial data with fractional polynomials and piecewise regression to obtain survival hazard functions over time, adjusting for patient characteristics, whereas others \[[@CR43]\] employed the life-table method to calculate a gain in life-years, estimating the probability of death using the relative risk of treatment versus placebo from trial data. Certain publications \[[@CR46], [@CR56]\] extrapolated clinical trial data within the post-observational period, with others \[[@CR16]\] assuming that the treatment efficacy for intervention and placebo declined at the same rate. One publication \[[@CR30]\] described the uncertainty for life expectancy values, which was estimated using three external sources. However, given the disparity in population outcomes that were derived from the external sources, these results were considered conservative only \[[@CR43]\]. Other approaches that were utilized included a discrete-event simulation (*n* = 6 \[9%\]) \[[@CR31], [@CR35], [@CR41], [@CR47], [@CR50], [@CR77]\]. Two of these studies were derived from health technology assessments \[[@CR31], [@CR47]\]. All six articles relied on the use of clinical trial data \[[@CR31], [@CR35], [@CR41], [@CR47], [@CR50], [@CR77]\], some of which underlined a shorter trial duration \[[@CR31], [@CR41], [@CR50]\] as these trials were terminated early because of the favourable treatment efficacy of the intervention, which in turn, may have influenced model assumptions regarding the initial long-term efficacy assigned to the treatments involved.

### Partition-Type Survival Modelling {#Sec13}

Some articles used a real-world partition-type survival analysis (*n* = 5 \[8%\]) \[[@CR53], [@CR63]--[@CR65], [@CR70]\] to evaluate the cost effectiveness of a specific intervention. All publications used the area between Kaplan--Meier curves or time-to-failure survival modelling to estimate differences in life-years gained, hospitalizations and other outcomes between treatment arms. Some indicated that trial data may have underestimated the economic benefit of the intervention by omitting non--study-related physician appointments and laboratory tests \[[@CR63], [@CR70]\]. Information regarding hospital length-of-stay statistics \[[@CR63], [@CR65]\] or estimated survival rates for the various treatment groups \[[@CR63]\] were absent from a number of publications. Most often, differences between treatment arms were captured by the disparity in area under the curves for the probability of first hospitalization as well as the number of life-years gained. Two other publications also used survival analytic models for assessment but did not describe their approach to model structure and specifications \[[@CR71], [@CR78]\].

### Decision Tree Modelling {#Sec14}

One publication based their model on the use of a decision tree approach \[[@CR20]\]. The absence of Markov nodes made it challenging to assess the overall economic impact, given this study only included a shorter timeline (i.e. maximum duration of 6 months), offering limited insight into the long-term economic implications associated with HF.

Health States, Utilities, and Resource Information {#Sec15}
--------------------------------------------------

All study types implemented either a cost-utility (*n* = 27 \[42%\]) or cost-effectiveness approach (*n* = 36 \[56%\]), with the exception of one publication that used a cost-minimization method \[[@CR28]\]. Time horizons tended to vary in duration across publications, ranging from 12 months to a lifetime horizon (Table [1](#Tab1){ref-type="table"}). Most of the models included a health system perspective, with models in a further nine publications based on a societal perspective. The applied discount rates were typically in the range of 3--6%, depending on where the publication originated (Table [1](#Tab1){ref-type="table"}). A total of 19 studies included information outlining hospitalization states for modelling patient outcomes and associated costs (Fig. [2](#Fig2){ref-type="fig"}). The majority (*n* = 14 \[22%\]) of these health-state types were generally classified as hospitalization.Fig. 2Hospitalization states utilized by a selection of retrieved studies during model construction for evaluating patient outcomes and associated costs. *ED* emergency department, *ICU* intensive care unit

Modelling Outcomes and Sensitivity Analyses {#Sec16}
-------------------------------------------

The bulk of the publications assessed more than one type of study outcome (Table [1](#Tab1){ref-type="table"}). These typically included overall costs (*n* = 59 \[92%\]), incremental cost-effectiveness ratios (ICERs) (*n* = 55 \[86%\]), life-years gained (*n* = 48 \[75%\]) and willingness-to-pay (WTP) thresholds (*n* = 37 \[58%\]). Figure [3](#Fig3){ref-type="fig"} displays the range of ICERs and WTP thresholds that were obtained according to study outcomes and regions assessed across the retrieved articles. The majority of analyses were evaluated from a US and UK healthcare perspective and used a drug versus placebo approach to establish cost effectiveness. ICERs captured within the UK were typically below the classic threshold of £20,000 per quality-adjusted life-year (QALY), with similar observations found according to US thresholds (i.e. most below \$US50,000 per QALY). Overall, within the included studies, active treatments (drug vs. drug) yielded higher ICERs than drug versus placebo comparisons (Fig. [3](#Fig3){ref-type="fig"}). There were many contributing factors, due to marginal utility gains and higher prices, driving ICER values upwards. It is fair to say that the value of an ICER would be expected to drop with the introduction of new drugs to the market; however, ICER values for drug versus placebo were generally less than drug versus drug comparisons. ICERs also varied widely across countries, partly due to varying approaches within modelling structures and specifications as well as the use and consideration of costs, patient utilities and health gains employed (Fig. [3](#Fig3){ref-type="fig"}). Other outcomes that were frequently evaluated included QALYs (*n* = 32 \[50%\]), with fewer publications (*n* = 4 \[6%\]) appearing to focus on value-based pricing as a study outcome (Table [1](#Tab1){ref-type="table"}).Fig. 3Frequency and range of incremental cost-effectiveness ratios and willingness-to-pay thresholds according to study outcomes derived from retrieved articles and regions. *AUD* Australian dollar, *CAD* Canadian dollar, *EUR* Euro, *GBP* British pound, *ICER* incremental cost-effectiveness ratio, *LYG* life-years gained, *QALY* quality-adjusted life-year, *SEK* Swedish krona, *USD* United States dollar

A modest number of the retrieved publications performed scenario (*n* = 4 \[6%\]) \[[@CR52], [@CR53], [@CR67], [@CR69]\] and sensitivity analyses, particularly deterministic sensitivity analysis (*n* = 19 \[30%\]) \[[@CR23], [@CR26], [@CR31], [@CR39]--[@CR41], [@CR43], [@CR47], [@CR50], [@CR51], [@CR58], [@CR62]--[@CR65], [@CR70]--[@CR72], [@CR75]\] or probabilistic sensitivity analysis (*n* = 12 \[19%\]) \[[@CR22], [@CR23], [@CR29], [@CR39]--[@CR41], [@CR47], [@CR49], [@CR60], [@CR61], [@CR71], [@CR73]\]. Although the types of sensitivity analyses were not specified in the remainder of the included publications, most studies were capable of establishing key model drivers. Several components that emerged as key model drivers included the probability of death/survival (*n* = 19 \[30%\]) \[[@CR17], [@CR18], [@CR21], [@CR23], [@CR27], [@CR32], [@CR33], [@CR35], [@CR36], [@CR45], [@CR48], [@CR49], [@CR51], [@CR56], [@CR59]--[@CR61], [@CR69], [@CR75]\], (re)hospitalizations (*n* = 15 \[23%\]) \[[@CR17], [@CR31], [@CR41], [@CR42], [@CR45], [@CR46], [@CR50], [@CR52], [@CR56], [@CR57], [@CR63], [@CR65], [@CR68]--[@CR70]\], treatment efficacy duration (*n* = 12 \[19%\]) \[[@CR15], [@CR17], [@CR22], [@CR32], [@CR33], [@CR39], [@CR40], [@CR44], [@CR53], [@CR58], [@CR65], [@CR70]\] and cost of treatment (*n* = 9 \[14%\]) \[[@CR15], [@CR16], [@CR18], [@CR21], [@CR41], [@CR43], [@CR50], [@CR51], [@CR72]\].

Modelling Disease Type and Classifications {#Sec17}
------------------------------------------

The majority of published models (40 publications \[64%\]) \[[@CR15], [@CR16], [@CR19], [@CR22]--[@CR28], [@CR32]--[@CR34], [@CR36]--[@CR43], [@CR45]--[@CR48], [@CR51], [@CR52], [@CR54], [@CR57], [@CR58], [@CR62], [@CR66]--[@CR69], [@CR72], [@CR73], [@CR75]--[@CR77]\] focused on patient populations that presented with chronic HF, with only two (3%) \[[@CR18], [@CR60]\] and three studies (5%) \[[@CR55], [@CR56], [@CR64]\] conducting their economic assessment according to patients with acute HF or a mixture of both HF types, respectively (Table [1](#Tab1){ref-type="table"}). Descriptions of patient HF types were unclear in the remaining 19 publications (28%). With the majority of economic models specific to chronic HF, unsurprisingly, these findings were largely similar to the trends (i.e. for model specifications and structure) documented for the overall number of publications (Table [1](#Tab1){ref-type="table"}). Comparison of the acute HF publications with the overall review findings was not feasible given the paucity of studies that focused solely on acute HF. Likewise, studies in this review that focused on acute and chronic HF (i.e. mixed) concurrently for economic evaluation were also limited. Additional subsets of HF assessed within the retained articles were examined; they included HFrEF (*n* = 45 \[70%\]), HFpEF (*n* = 6 \[9%\]) and both mixed HF subtypes (*n* = 2 \[3%\]), with the remainder of publications (*n* = 11 \[17%\]) not reporting a specific HF subtype. Given the lack of differentiation across papers and how they defined patients with HFrEF and HFpEF, it was also not possible to conduct any comparison according to publications and their patient subsets. A total of 41 publications (64%) \[[@CR15]--[@CR17], [@CR19], [@CR20], [@CR22], [@CR23], [@CR25], [@CR27], [@CR28], [@CR32]--[@CR34], [@CR38]--[@CR42], [@CR45]--[@CR48], [@CR51]--[@CR53], [@CR57], [@CR59], [@CR60], [@CR62]--[@CR70], [@CR73], [@CR75]--[@CR77]\] used the NYHA disease classification system to categorize patients and determine the severity of HF, of which 34 (83%) \[[@CR15]--[@CR17], [@CR19], [@CR22], [@CR23], [@CR25], [@CR27], [@CR28], [@CR32]--[@CR34], [@CR38]--[@CR42], [@CR45]--[@CR47], [@CR51], [@CR52], [@CR57], [@CR59], [@CR62], [@CR64], [@CR66]--[@CR69], [@CR73], [@CR75]--[@CR77]\] focused on patients assigned to NYHA classifications II--III. The observed model structures and specifications within these publications were similar to those found according to the overall number of HF publications (Table [1](#Tab1){ref-type="table"}). Only one publication (2%) \[[@CR55]\] employed the Killip classification system, and definitions of disease classification were unclear in the remainder (*n* = 22 \[34%\]) (Table [1](#Tab1){ref-type="table"}).

Quality of Available Publications {#Sec18}
---------------------------------

In total, 63 publications (98%) were eligible for quality assessment using the CHEERS checklist (Table [2](#Tab2){ref-type="table"}). One study was omitted from quality assessment as only the abstract was presented in English \[[@CR73]\]. The majority of checklist items according to the six main category domains were shown to be documented within publications, and most of the included articles demonstrated reasonable methodological quality (Table [2](#Tab2){ref-type="table"}). However, some of the publications only reported on certain items, including "measurement of effectiveness" of data (*n* = 31 \[49%\] for both sub-items), "measurement and valuation of performance-based outcomes" (*n* = 25 \[40%\]), information regarding "estimation of resources and costs" (*n* = 22 \[35%\] for item A; *n* = 35 \[55%\] for item B), as well as "characterizing uncertainty" (*n* = 22 \[35%\] for item A; *n* = 36 \[56%\] for item B) and "heterogeneity" (*n* = 38 \[60%\]) (Table [2](#Tab2){ref-type="table"}).Table 2Overview of the quality of included publications according to the CHEERS checklistItem no.ItemDescriptionPublication response (*n*)^a^Publication response (%)^b^TrueFalseUnclearNATrueFalseUnclearNATitle and abstract 1TitleIdentify the study as an economic evaluation, or use more specific terms such as 'cost-effectiveness analysis' and describe the interventions compared63^a^000100000 2AbstractProvide a structured summary of objectives, perspective, setting, methods (including study design and inputs), results (including base-case and uncertainty analyses), and conclusions54108862012Introduction 3Background and objectivesProvide an explicit statement of the broader context for the study. Present the study question and its relevance for health policy or practice decisions63000100000Methods 4Target population and subgroupsDescribe characteristics of the base-case population and subgroups analysed, including why they were chosen6201098200 5Setting and locationState relevant aspects of the system(s) in which the decision(s) need(s) to be made6003095500 6Study perspectiveDescribe the perspective of the study and relate this to the costs being evaluated5805092080 7ComparatorsDescribe the interventions or strategies being compared and state why they were chosen63000100000 8Time horizonState the time horizon(s) over which costs and consequences are being evaluated and say why appropriate63000100000 9Discount rateReport the choice of discount rate(s) used for costs and outcomes and say why appropriate5760091900 10Choice of health outcomesDescribe what outcomes were used as the measure(s) of benefit in the evaluation and their relevance for the type of analysis performed63000100000 11aMeasurement of effectivenessSingle-study-based estimates: Describe fully the design features of the single effectiveness study and why the single study was a sufficient source of clinical-effectiveness data310032490051 11bSynthesis-based estimates: Describe fully the methods used for the identification of included studies and synthesis of clinical-effectiveness data311031492049 12Measurement and valuation of preference-based outcomesIf applicable, describe the population and methods used to elicit preferences for outcomes256230409348 13aEstimating resources and costsSingle-study-based economic evaluation: Describe approaches used to estimate resource use associated with the alternative interventions. Describe primary or secondary research methods for valuing each resource item in terms of its unit cost. Describe any adjustments made to approximate to opportunity costs221040352063 13bModel-based economic evaluation: Describe approaches and data sources used to estimate resource use associated with model health states. Describe primary or secondary research methods for valuing each resource item in terms of its unit cost. Describe any adjustments made to approximate to opportunity costs350523550837 14Currency, price date, and conversionReport the dates of the estimated resource quantities and unit costs. Describe methods for adjusting estimated unit costs to the year of reported costs, if necessary. Describe methods for converting costs into a common currency base and the exchange rate5616089290 15Choice of modelDescribe and give reasons for the specific type of decision analytic model used. Providing a figure to show model structure is strongly recommended56700891100 16AssumptionsDescribe all structural or other assumptions underpinning the decision analytic model5805092080 17Analytic methodsDescribe all analytic methods supporting the evaluation. This could include methods for dealing with skewed, missing or censored data; extrapolation methods; methods for pooling data; approaches to validate or make adjustments (e.g. half-cycle corrections) to a model; and methods for handling population heterogeneity and uncertainty51390815140Results 18Study parametersReport the values, ranges, references and, if used, probability distributions for all parameters. Report reasons or sources for distributions used to represent uncertainty where appropriate. Providing a table to show the input values is strongly recommended55170872110 19Incremental costs and outcomesFor each intervention, report mean values for the main categories of estimated costs and outcomes of interest, as well as mean differences between the comparator groups. If applicable, report incremental cost-effectiveness ratios6102097030 20aCharacterizing uncertaintySingle-study-based economic evaluation: Describe the effects of sampling uncertainty for estimated incremental cost, incremental effectiveness, and incremental cost effectiveness, together with the impact of methodological assumptions (such as discount rate, study perspective)220140350263 20bModel-based economic evaluation: Describe the effects on the results of uncertainty for all input parameters, and uncertainty related to the structure of the model and assumptions363123565237 21Characterizing heterogeneityIf applicable, report differences in costs, outcomes or cost effectiveness that can be explained by variations between subgroups of patients with different baseline characteristics or other observed variability in effects that are not reducible by more information38151006024160Discussion 22Study findings, limitations, generalizability, and current knowledgeSummarize key study findings and describe how they support the conclusions reached. Discuss limitations and the generalizability of the findings and how the findings fit with current knowledge5436086590Other 23Source of fundingDescribe how the study was funded and the role of the funder in the identification, design, conduct and reporting of the analysis. Describe other nonmonetary sources of support4611067317010 24Conflicts of interestDescribe any potential for conflict of interest among study contributors in accordance with journal policy. In the absence of a journal policy, we recommend authors comply with International Committee of Medical Journal Editors' recommendations468187313212*CHEERS* Consolidated Health Economic Evaluation Reporting Standards^a^Total *n* assessed by checklist was 63; one publication was unavailable in English \[[@CR73]\]^b^The publication number (*n *= 63) included in this quality assessment was used as the denominator for completeness of study information

Discussion {#Sec19}
==========

In this review, we sought to describe the methodological components currently available for use in the economic evaluation of HF, with the intention of guiding future decision analytic models aimed at assessing the cost effectiveness of treatment strategies in the field of HF management. We identified 64 modelling studies, most of which displayed suitable methodological quality. The retrieved models typically employed a Markov or trial-based analytic approach and displayed sufficient details about model perspectives and discount rates. Several recurring outcomes appeared to be commonly assessed within each model, including total costs, ICERs, life-years gained, WTP and QALYs.

Some variability in model structure was evident across the retrieved publications because of the disparity in choice of time horizons used, which ranged from 12 months to a lifetime. We observed a trend away from cost-effectiveness analysis carried out using clinical trial data (or extrapolations from these) towards a modelling-based approach using, for example, Markov modelling. Less than half (i.e. 41%) of the retrieved publications specified their use of deterministic sensitivity/scenario analysis and/or probabilistic sensitivity analysis \[[@CR79]\]. We consider this finding a missed opportunity to assess in detail the parameter uncertainty and the impact of key variables in the cost-effectiveness profiles. Further, although this review identified a number of decision analytic models in the HF setting, collectively, the variability that existed across these models rendered it a challenge to perform a more comprehensive comparison of the retrieved findings. Varying degrees of severity were also found for hospitalization and/or cardiovascular outcomes that were modelled across treatment arms. Some studies tended to use hazard ratios and probabilities from clinical trial data in an effort to estimate the relative probability of HF and hospitalization between treatments. In one publication \[[@CR39]\], regression equations employed clinical trial data to determine the treatment effect, whereas other studies used statistical distributions along with survival curves to define clinical efficacies, outcomes and death. Moreover, the rate of survival was frequently derived using time-constant probabilities that differed across treatment arms, health states and/or time horizons \[[@CR32], [@CR34]\]. Other studies tended to calculate mortality as a function of age and sex \[[@CR68]\] or by use of survival tables \[[@CR75]\]. The complexity of these different methodologies underlines the importance of exploring the most suitable modelling approaches, depending on the research question at hand, for appropriately and reliably conducting economic assessments in the management of HF.

Most studies employed NYHA disease classifications for establishing disease severity among patients for modelling purposes. Yet, it remains questionable whether the predominant use of this instrument (as observed in this review) is appropriate, given limitations around reproducibility, reliability, and clinician's interpretation of what construes "normal" in patients who present with HF \[[@CR80]--[@CR82]\]. Although NYHA functional classification represents a useful clinical measure for defining patient-relevant disease status, alternative classifications may need to be developed to reliably assess disease progression. Our observations support the views of Goehler et al. \[[@CR9]\], who documented that most prior models exclusively used NYHA classification as a function of defining disease status, progression and prognosis. From a modelling perspective, the heterogeneity in profiles of patients with HF indicate that sole use of the NYHA instrument to measure disease status is insufficient. Moreover, there is some debate as to how individual clinicians employ the NYHA classifications for evaluating HF severity among patients, with their approaches often considered unclear \[[@CR82]\]. Additionally, novel approaches, such as those that implement machine-learning algorithms, would likely extend our understanding of how to select the most suitable candidate predictors in HF \[[@CR83], [@CR84]\], through identifying important clusters of risk factors that would facilitate our approach to quantifying disease status in the management and evaluation of HF.

Not all retrieved publications reported details on hospitalizations (e.g. as a health state) when evaluating the costs associated with HF. Of the few studies that provided sufficient information, the majority were classified as general hospitalization. Of those few publications that defined a specific hospitalization type for determining health states, two were classed as emergency department visits, one specified an intensive care unit visit; and two other publications specified a short-term and a ward hospitalization, respectively. Indicators of (re)hospitalization can provide crucial information beyond classification instruments and offer further details about the patient profile, thus proving useful to the modeller when attempting to evaluate the economic and societal implications in HF. Nevertheless, the use of generalized indicators for hospitalization in a model structure should be given careful consideration, alongside any potential for bias or skewing. For example, if hospitalization is only considered as a single Markov state, or if only one hospitalization can occur within one model cycle, a skewing in observations and related costs could occur depending on the actual type and number of hospital visit(s) or actual duration of hospital stays. This is a particular consideration in a chronic condition such as HF, where frequent rehospitalizations are very common \[[@CR1], [@CR8]\]. Although both hospitalization and NYHA disease classifications may offer a more comprehensive assessment of disease status when combined, additional research is undoubtedly needed to help further underline the utility of both measures and their reliability to act as surrogates of HF when attempting to capture disease status, progression and prognosis.

On the background of these reasons, further investigation is warranted to determine more reliable candidates of disease progression that will facilitate forthcoming development of decision analytic models. At minimum, these measures are expected to be readily accessible, straightforward to quantify and have the capacity to provide added value to a model over and above existing parameters (i.e. NYHA class and hospitalization) \[[@CR32]\]. Depending on the availability of data and outcomes to be modelled, regression equation modelling such as Poisson and negative binomial regression models could potentially enhance the modelling approach for determining the likelihood that a patient might experience a hospitalization event. Although a number of parametric distributions estimating survival data beyond the measured period provide plausible estimates and an alternative to the Cox model, they do compromise on their restrictions on the shape of the hazard function, often causing an over-estimation in the treatment effect \[[@CR32]\]. To overcome this problem, it is worth considering more flexible parametric models such as restricted cubic splines to enable modelling of the baseline hazard. This approach offers advantages of greater flexibility in the shape of the hazard function, particularly when compared with the parametric modelling approach.

Limitations {#Sec20}
-----------

Some limitations inherent to this review need to be emphasized. It was not our intention to offer a comprehensive evaluation of the results of the retrieved studies but rather to provide an overview of similar model features that were employed. It should be borne in mind that each publication differs according to their overall aims, target population considered, health procedures assessed and accessibility to study data. To this end, advocating an optimal modelling approach for use in the HF setting was beyond the scope of this review. Exploring the various economic models according to HF patient subsets, particularly those who presented with either HFrEF or HFpEF, was challenging given the disparity in study sample classifications observed across the retrieved articles. Hence, disentangling the similarities in model structures to identify clear trends in specifics of methodology is beyond the scope of our analysis. In addition, how to best identify key model drivers and specifications according to HF subtypes warrants further investigation. Indeed, we encourage health economics modellers involved in HF treatment assessments to perform value of information analyses (at least expected value of perfect information \[EVPI\] and expected value of perfect parameter information \[EVPPI\]) to better evaluate the value of the expected benefit of further investigating uncertain parameters in the decision model \[[@CR85]\]. Only models derived from full-text publications were included, and we did not seek direct communication with the corresponding authors of these articles. On this basis, our understanding of the retrieved models is expected to be limited, particularly considering each publication seldom displays all available information because of publication constraints typically administered by journals. As such, we cannot discount the possibility that certain model elements of interest (e.g. as documented in technical modelling reports) may have been overlooked by the present review. We employed a study inclusion window of 20 years for the current analysis. As such, we cannot discount the possibility that other studies deemed suitable for inclusion into this SLR have since been published.

Conclusion {#Sec21}
==========

Numerous decision analytic modelling approaches for evaluating the cost effectiveness of HF treatments have been adopted, with a Markov cohort model proving to be the most commonly used approach. The majority of the models tended to differ in structure as well as health states and frequently relied upon the use of NYHA disease classification as a surrogate of disease severity, progression and prognosis. Recognizing alternative and more succinct approaches for the purpose of defining an optimal model structure would undoubtedly permit for a more precise estimation of the associated costs incurred, while facilitating clinical decision making in the management of HF.

Electronic supplementary material
=================================

 {#Sec22}

Below is the link to the electronic supplementary material. Supplementary material 1 (PDF 97 kb)

Funding {#FPar2}
=======

This study was funded by Amgen, GmbH, Zug, Switzerland. Neither honoraria nor payments were provided for authorship.

The authors thank Mitesh Nakum, MSc., and Abigail Shields, MSc. (Curo Payer Evidence, part of the Envision Pharma Group), for their useful insights and assistance and also Benjamin Cohen (University of Southern California) for his preliminary extraction on a short review conducted during his 2017 Summer Internship at Amgen.

All authors adhered to the ICMJE authorship criteria. GL Di Tanna and G Globe planned and designed this study. GL Di Tanna, A Bychenkova and F O'Neill conducted the review, screened the studies and extracted the information. All authors were involved in the data analysis and interpretation, initial drafting of the manuscript, and review and final approval of the manuscript for submission.

Conflict of interest {#FPar3}
====================

GL Di Tanna, A Bychenkova, H Wirtz, and G Globe are employees of Amgen and may hold corporate stock in Amgen. H Wirtz also holds corporate stock in Teva Pharmaceutical Industries Ltd. F O'Neill was an employee of Amgen until April 2018. P Miller has previously consulted for AstraZeneca, GSK, Pfizer, Novartis, Roche, Chiesi, and Bayer. B Ó Hartaigh was an employee of Curo, part of the Envision Pharma Group, when the study was conducted, who was contracted by Amgen to provide editorial support in the preparation of this manuscript.

Statement of human rights and/or animals {#FPar4}
========================================

For this type of study, formal consent is not required.

Data availability {#FPar5}
=================

Data sharing is not applicable to this article as no datasets were generated or analysed during the current review.
